Search

everythinglearnresearchcommunity

for

Search:↓

The document suggests more research is needed to understand the link between baldness and prostate cancer.

Serum triglyceride levels are not linked to prostate cancer risk.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Finasteride effectively treats BPH but may increase sexual dysfunction risk.

Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.

Testosterone therapy increases bone density in older men with low testosterone levels.

Targeting colon cancer stem cells might lead to better treatment results.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Targeting androgen receptors could be a promising way to treat skin disorders with fewer side effects.

Minoxidil and finasteride can slow hair loss and stimulate regrowth, but won't restore all lost hair or reverse complete baldness.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

Finasteride doesn't harm male fertility or sperm quality, but may slightly reduce ejaculate volume.

Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Black ethnicity, prior PSA tests, enlarged prostate, and family history increase prostate cancer risk; Asian ethnicity, obesity, smoking, diabetes, and less sexual activity or no children decrease risk.

Finasteride didn't significantly improve ICPPS symptoms, more research needed.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Finasteride reduces hair loss and treats BPH without major hormone changes, but may cause sexual dysfunction.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Finasteride effectively improves hair growth and slows hair loss in men with male pattern baldness.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

Early hair loss may indicate prostate issues.

Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.

Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.

Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.

Transgender patients need proper skin care, especially when undergoing hormone treatments, to manage issues like acne and hair loss.